18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond

Rodney J. Hicks; Amir Iravani; Shahneen Sandhu

doi:10.1016/j.cpet.2019.08.007

¹⁸F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond

Rodney J. Hicks, Amir Iravani, Shahneen Sandhu

Research output: Contribution to journal › Review article › peer-review

21 Scopus citations

Abstract

The complexity of the immune response and diversity of targets challenges conventional conceptual frameworks used in selecting and monitoring treatment with immune check-point inhibitors. The limitations of anatomic imaging in assessing response have been recognized. Varying patterns of response have been recognized. These patterns have different implications for the continuation and duration of therapy. Evidence supporting the role of ¹⁸F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography as a prognostic biomarker and in characterizing response is presented. An added benefit of this approach is the ability to detect immune-related inflammatory reactions, often in advance of severe or life-threatening clinical manifestations.

Original language	English
Pages (from-to)	11-22
Number of pages	12
Journal	PET Clinics
Volume	15
Issue number	1
DOIs	https://doi.org/10.1016/j.cpet.2019.08.007
State	Published - Jan 2020

Keywords

Biomarkers
FDG
Immunotherapy
Melanoma
Non-small cell lung cancer
PET/CT
Therapeutic monitoring

Access to Document

10.1016/j.cpet.2019.08.007

Cite this

@article{d6b5eca34c6d46a69a9126b9f82af0b9,

title = "18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond",

abstract = "The complexity of the immune response and diversity of targets challenges conventional conceptual frameworks used in selecting and monitoring treatment with immune check-point inhibitors. The limitations of anatomic imaging in assessing response have been recognized. Varying patterns of response have been recognized. These patterns have different implications for the continuation and duration of therapy. Evidence supporting the role of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography as a prognostic biomarker and in characterizing response is presented. An added benefit of this approach is the ability to detect immune-related inflammatory reactions, often in advance of severe or life-threatening clinical manifestations.",

keywords = "Biomarkers, FDG, Immunotherapy, Melanoma, Non-small cell lung cancer, PET/CT, Therapeutic monitoring",

author = "Hicks, {Rodney J.} and Amir Iravani and Shahneen Sandhu",

note = "Funding Information: Disclosure Statement: Professor Hicks is supported by a Practitioner Fellowship of the National Health and Medical Research Council of Australia (APP1108050). He holds shares in Telix Pharmaceuticals. The other authors have nothing to disclose. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = jan,

doi = "10.1016/j.cpet.2019.08.007",

language = "English",

volume = "15",

pages = "11--22",

journal = "PET Clinics",

issn = "1556-8598",

number = "1",

}

TY - JOUR

T1 - 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors

T2 - Melanoma and Beyond

AU - Hicks, Rodney J.

AU - Iravani, Amir

AU - Sandhu, Shahneen

N1 - Funding Information: Disclosure Statement: Professor Hicks is supported by a Practitioner Fellowship of the National Health and Medical Research Council of Australia (APP1108050). He holds shares in Telix Pharmaceuticals. The other authors have nothing to disclose. Publisher Copyright: © 2019 Elsevier Inc.

PY - 2020/1

Y1 - 2020/1

N2 - The complexity of the immune response and diversity of targets challenges conventional conceptual frameworks used in selecting and monitoring treatment with immune check-point inhibitors. The limitations of anatomic imaging in assessing response have been recognized. Varying patterns of response have been recognized. These patterns have different implications for the continuation and duration of therapy. Evidence supporting the role of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography as a prognostic biomarker and in characterizing response is presented. An added benefit of this approach is the ability to detect immune-related inflammatory reactions, often in advance of severe or life-threatening clinical manifestations.

AB - The complexity of the immune response and diversity of targets challenges conventional conceptual frameworks used in selecting and monitoring treatment with immune check-point inhibitors. The limitations of anatomic imaging in assessing response have been recognized. Varying patterns of response have been recognized. These patterns have different implications for the continuation and duration of therapy. Evidence supporting the role of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography as a prognostic biomarker and in characterizing response is presented. An added benefit of this approach is the ability to detect immune-related inflammatory reactions, often in advance of severe or life-threatening clinical manifestations.

KW - Biomarkers

KW - FDG

KW - Immunotherapy

KW - Melanoma

KW - Non-small cell lung cancer

KW - PET/CT

KW - Therapeutic monitoring

UR - http://www.scopus.com/inward/record.url?scp=85074870805&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2019.08.007

DO - 10.1016/j.cpet.2019.08.007

M3 - Review article

C2 - 31735298

AN - SCOPUS:85074870805

SN - 1556-8598

VL - 15

SP - 11

EP - 22

JO - PET Clinics

JF - PET Clinics

IS - 1

ER -

¹⁸F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this